Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Decrease in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 49,958 shares, a decrease of 32.3% from the July 30th total of 73,790 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 50,520 shares, the days-to-cover ratio is currently 1.0 days.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is currently owned by institutional investors and hedge funds.

Dogwood Therapeutics Trading Up 3.5%

Shares of NASDAQ:DWTX traded up $0.09 during trading on Tuesday, reaching $2.67. The company had a trading volume of 91,382 shares, compared to its average volume of 77,845. The company has a fifty day moving average of $1.77 and a two-hundred day moving average of $1.99. The stock has a market capitalization of $90.79 million, a P/E ratio of -0.29 and a beta of 1.71. Dogwood Therapeutics has a 12 month low of $1.28 and a 12 month high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20). As a group, equities research analysts predict that Dogwood Therapeutics will post -0.67 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on DWTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Dogwood Therapeutics in a report on Tuesday, May 19th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dogwood Therapeutics has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.